IL2 and melanoma: TILs are endogenous, polyclonal lymphocytes harvested from resected tumors, expanded in interleukin-2, and reinfused following lymphodepletion—capitalizing on the natural breadth of tumor antigen recognition and showing long-lasting responses in melanoma and other solid cancers.